Prestige BioPharma Limited (KRX:950210)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,020.00
-40.00 (-0.44%)
Last updated: Apr 29, 2026, 1:50 PM KST
-40.93%
Market Cap 108.65B
Revenue (ttm) 19.02B
Net Income (ttm) 13.68B
Shares Out 12.02M
EPS (ttm) 227.41
PE Ratio 39.75
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,368
Average Volume 76,421
Open 9,060.00
Previous Close 9,060.00
Day's Range 9,010.00 - 9,130.00
52-Week Range 8,900.00 - 20,000.00
Beta 0.73
RSI 39.63
Earnings Date May 29, 2026

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Singapore
Stock Exchange Korea Stock Exchange
Ticker Symbol 950210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.